Market research
CXF.F Chimerix, Inc
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 703M
- P/E ratio
- 0.0
- Analyst target
- 17.67
- Dividend yield
- Not available
- Beta
- -0.61
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- US16934W1062
- Market cap
- 703M
- P/E ratio
- 0.0
- Analyst target
- 17.67
- Dividend yield
- Not available
- Beta
- -0.61
About
About Chimerix, Inc
Chimerix, Inc. develops medicines to improve and extend the lives of patients facing deadly diseases in the United States. Its product pipeline comprises dordaviprone (ONC201), which is in phase 3 clinical-stage development for H3 K27M-mutant diffuse glioma, as well as in phase 2 Investigator Initiated Clinical Trials for multiple oncology studies; and ONC206, a second generation imipridone ClpP agonist and DRD2 antagonist which is in phase 1 clinical trial to treat central nervous systems and other solid tumors. The company also develops ONC212, an imipridone, an investigational agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP, which is in preclinical trials; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of novel coronaviruses. In addition, it offers TEMBEXA, a lipid conjugate which acts via inhibition of viral DNA synthesis, which is a medical countermeasure for smallpox. The company was incorporated in 2000 and is based in Durham, North Carolina. As of April 21, 2025, Chimerix, Inc. operates as a subsidiary of Jazz Pharmaceuticals plc.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the CXF.F discussion.
5 years, 4 months ago
Chimerix, Inc is currently in a long term uptrend where the price is trading 10.9% above its 200 day moving average.
From a valuation standpoint, the stock is 91.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 109.9.
Chimerix, Inc's total revenue sank by 83.4% to $1M since the same quarter in the previous year.
Its net income has dropped by 233.3% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 160.2% to $-9M since the same quarter in the previous year.
Based on the above factors, Chimerix, Inc gets an overall score of 2/5.